Cargando…
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
PURPOSE: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (T...
Autores principales: | Grisic, Ana-Marija, Xiong, Wenyuan, Tanneau, Lénaïg, Jönsson, Siv, Friberg, Lena E., Karlsson, Mats O., Dai, Haiqing, Zheng, Jenny, Girard, Pascal, Khandelwal, Akash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365383/ https://www.ncbi.nlm.nih.gov/pubmed/34921021 http://dx.doi.org/10.1158/1078-0432.CCR-21-2662 |
Ejemplares similares
-
Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors
por: Vugmeyster, Yulia, et al.
Publicado: (2022) -
Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
por: Wilkins, Justin J., et al.
Publicado: (2019) -
A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
por: Liu, Han, et al.
Publicado: (2023) -
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020) -
Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma
por: Novakovic, Ana M., et al.
Publicado: (2019)